[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"botox\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:botox":56},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,90],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643880","intraarticular-injection-of-botox-and-hyaluronic-acid-in-knee-osteoarthritis-100643880",false,"NCT07666347","Intraarticular Injection of Botox and Hyaluronic Acid in Knee Osteoarthritis","Inclusion Criteria:\n\n* Age ≥ 50 years.\n* Both genders.\n* Chronic knee osteoarthritis (KOA) according to American College of Rheumatology criteria for the diagnosis of knee osteoarthritis.\n* Third or fourth grade Kellgren and Lawrence system for classification of osteoarthritis based on radiological data, it is a common method of classifying the severity of osteoarthritis (OA) using five grades according to the following sites and projections.\n\nExclusion Criteria:\n\n* History of intra-articular injection within the last 6 months,\n* History of surgery on the knee joint or major trauma to the lower limb causing fracture.\n* Body mass index (BMI) more than 40 kg\u002Fm2.\n* Medical conditions affecting the joint or lower extremity function such as severe osteoporosis, rheumatoid arthritis, collagen vascular diseases, and gout.\n* Diabetic patient.\n* Any contraindication to intra-articular injections for instance immunodeficiency, coagulation defect or anticoagulation therapy taking or skin infection at the site of injection.\n* Hypersensitivity to Botulinum toxin or hyaluronic acid.","ALL","50 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study aims to compare the efficacy of intra-articular injection of Botulinum toxin and hyaluronic acid on pain in knee osteoarthritis.",[25,26,27,28],"Intraarticular Injection","Botox","Hyaluronic Acid","Knee Osteoarthritis","RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-25","ACTUAL",{"date":30,"type":33},{"date":36,"type":19},"2026-12-01",{"name":38,"class":39},"Tanta University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100590991","sphenopalatine-block-versus-botox-in-management-of-chronic-migraine-100590991","NCT06974617","Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine","Sphenopalatine Block Versus BOTOX in Management of Chronic Migraine: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 and 65 years.\n* Both sexes.\n* Chronic migraine. Chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to International Classification of Headache Disorders-3 Beta.\n\nExclusion Criteria:\n\n* Patients with medication over use headache.\n* Bleeding disorders.\n* Abnormal neurological examination.\n* History of allergy to local anesthetics or BOTOX.","18 Years","65 Years",{"count":51,"type":19},64,[22],"This trial compares the efficacy and safety of sphenopalatine ganglion block (SPGB) and intramuscular BOTOX injection in chronic migraine.",[55,56,57],"Sphenopalatine Block","BOTOX","Chronic Migraine","2025-05-15",{"date":60,"type":33},"2025-05-16",{"date":58,"type":33},{"date":63,"type":19},"2025-10-01",{"name":65,"class":39},"Cairo University",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":20,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100572540","phase-4-efficacy-of-botox-injection-of-the-masticatory-muscles-in-head-neck-cancer-patients-with-trismus-after-radiotherapy-100572540","NCT06734598","Efficacy of Botox Injection of the Masticatory Muscles in Head &Neck Cancer Patients with Trismus After Radiotherapy","Inclusion Criteria:\n\n1. Aged over 18 years old;\n2. Head and neck cancer patients must have completed radiotherapy for at least 3 months;\n3. Those whose mouth-opening distance is less than or equal to 3.5 cm (the functional cut-off point of trismus) and who have tightness or pain in the masticatory muscles;\n4. Medical condition is stable;\n\nExclusion Criteria:\n\n1. Those who have undergone surgery on their masticatory muscles;\n2. Patients with obvious muscle atrophy or complete fibrosis of masticatory muscles ;\n3. Those with tumor recurrence at the time of admission;\n4. Those whose vital signs are unstable due to acute illness.",{"count":73,"type":19},120,[75],"PHASE4","Trismus is a common side effect in head and neck cancer patients after radiation therapy. This project aims to explore the therapeutic effect of Botulinum toxin (Botox) injection to the masticatory muscles in the above-mentioned patients.\n\nIn this project, Botulinum toxin will be injected into the masticatory muscles (medial pterygoid and masticatory muscles), combined with oral rehabilitation exercises, to reduce the patient's masticatory muscle tension and spasm. Patient's mouth opening range, quality of life, trismus condition and pain will be evaluated to understand its efficacy.",[78,79,80,56],"Trismus","Head and Neck Cancer","Radiation Therapy Recipient","2024-12-12",{"date":83,"type":33},"2024-12-16",{"date":85,"type":33},"2024-12-01",{"date":87,"type":19},"2026-02-01",{"name":89,"class":39},"National Taiwan University Hospital",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":48,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":20,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":40},"100558655","mandibular-splint-vs-botox-injection-in-lateral-pterygoid-on-cervical-muscle-activity-in-patients-with-temporomandibular-disorders-100558655","NCT06553950","Mandibular Splint vs Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders","Mandibular Splint Versus Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders","Inclusion Criteria:\n\n* Age from 18-40 years old.\n* Both sexes.\n* Duration of the disease is more than 3 months.\n* Anterior mandibular disc displacement with reduction will be included.\n* Unilateral anterior mandibular displacement with reduction grade 2\\&3 (Wilkes) will be included.\n* Patients with cervical muscles spasm and trigger points (upper trapezius\\& sternocleidomastoid) will be included.\n* Patients with sufficient cognitive abilities that enables them to understand and follow instructions.\n\nExclusion Criteria:\n\n* Neurological or musculoskeletal diseases that affect cervical spine other than mandibular disc displacement (eg: cervical spondylosis, spondylolisthesis, and cervical disc injuries)\n* Bilateral anterior mandibular disc displacement patients.\n* Musculoskeletal disorders such as severe arthritis, cervical spine surgery or contractures of fixed deformity, leg length discrepancy.\n* women during pregnancy and lactation.\n* Patients with known hypersensitivity to any component of the drug (especially hypersensitivity to human albumin).\n* Patients with infection or inflammation of the area where the toxin injections are planned, in patients with musculoskeletal conduction disorders, in primary muscular disorders (muscular dystrophy, neuromyopathy, congenital myopathies, myotonic disorders, mitochondrial myopathy and unspecified or other primary muscle disorders).\n* Patients being treated with aminoglycoside antibiotics, ciclosporin, D-penicillamine, tubocurarine, pancuronium, gallamine, succinylcholine, chloroquine, or hydroxychloroquine.\n* History of cervical spine surgery.\n* History of trauma or fractures in cervical spine.\n* Signs of cervical radiculopathy or myelopathy.\n* Vascular syndrome such as vertebrobasilar insufficiency.\n* Signs of serious pathology ( e.g., malignancy, inflammatory disorders, infection).","40 Years",{"count":99,"type":19},33,[22],"The study aims to compere mandibular splint versus botox injection in lateral pterygoid on cervical muscle activity in patients with temporomandibular disorders",[103,26,104,105,106],"Mandibular Splint","Lateral Pterygoid","Cervical Muscle Activity","Temporomandibular Disorders","2024-08-14",{"date":109,"type":33},"2024-08-16",{"date":107,"type":33},{"date":112,"type":19},"2025-02-01",{"name":65,"class":39}]